Date: 2011-11-02
Type of information: Development agreement
Compound: next-generation sequencing for the rapid, accurate identification of patients\' infectious disease states and potential treatment paths.
Company: Illumina (USA) Siemens Healthcare Diagnostics (USA), subsidiary of Siemens AG (Germany)
Therapeutic area: Infectious diseases
Type agreement: development
Action mechanism:
Disease:
Details: Siemens Healthcare Diagnostics and Illumina have reached an agreement to "optimize the use of next-generation sequencers.\" This move towards personalized medicine will allow rapid and accurate determination of the infectious agent from a patient in order to establish the most appropriate treatment. With this agreement, the partners plan to make compatible the HIV test (TRUGENE ®) with the existing Siemens MiSeq sequencer Illumina ™, the ultimate goal being the rise of the sequencing technique in the arsenal of diagnostic tests of infectious diseases.
Financial terms: Financial details were not disclosed.
Latest news:
